Objectives: To characterize the population structure and resistance mechanisms of Klebsiella pneumoniae isolates that are highly resistant to third-generation cephalosporins, collected from five Spanish hospitals.
Introduction
Most countries have recently experienced rapid dissemination of extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae isolates. 1, 2 During the past decade, the CTX-M-type has represented the most rapidly growing group of ESBLs; specifically, CTX-M-15 has recently emerged as the dominant type of cefotaximase in Gram-negative pathogens, causing outbreaks in nosocomial and community settings. 3 -5 The clonal dissemination of CTX-M-15-producing Escherichia coli belonging to phylogenetic group B2 and sequence type (ST) 131 has been addressed in several different countries. 2, 3, 6, 7 Klebsiella pneumoniae is one of the most common Gram-negative bacteria showing resistance to multiple antibiotics worldwide. This opportunistic pathogen is responsible for nosocomial infections, primarily in intensive care units (ICUs) and newborn units (NUs), and represents a major clinical risk, especially for immunocompromised patients.
In invasive K. pneumoniae isolates collected throughout Spain, ESBL production has increased from 9.1% in 2006 to 12.4% in 2008 (European Antimicrobial Resistance Surveillance System, http://www.rivm.nl/earss/; last accessed 15 February 2009 ). Outbreaks of CTX-M-15-producing K. pneumoniae isolates have been recently described in some European countries, 5, 8 including one epidemic clone characterized by PFGE from a single institution in Madrid. 9 In addition, little is known about the population structure of CTX-M-15-producing K. pneumoniae causing outbreaks, as determined by multilocus sequence typing (MLST). Taking into account the reported worldwide clonal spread of CTX-M-15-producing E. coli, this information is of great clinical and epidemiological interest.
The purpose of this study was the characterization of the population structure and resistance mechanisms of K. pneumoniae isolates that are highly resistant to third-generation cephalosporins and other antibiotics, collected during 2008 from suspected outbreaks in five different Spanish hospitals located in three different provinces.
Material and methods

Study design and bacterial strains
During 2008, an unexpected increase was observed in the submission of K. pneumoniae isolates highly resistant to cefotaxime and ceftazidime to the Centro Nacional de Microbiología (CNM), a public health reference institution. This observation prompted the present investigation.
A total of 162 isolates of K. pneumoniae involved in suspected outbreaks were received and studied. These were submitted to the CNM to determine the molecular epidemiology of the isolates and the resistance mechanisms involved. The isolates were collected during 2008 from patients at five different hospitals (H1-H5) located in Málaga (H1 and H2), Madrid (H3 and H4) and Cádiz (H5); these five hospitals are located in three separated geographical areas of Spain. The distribution of the 162 isolates was as follows: 82 from H1; 54 from H2; 18 from H3; 3 from H4; and 5 from H5.
Bacterial identification and susceptibility testing
Bacterial identification and susceptibility testing was first carried out by each hospital microbiological laboratory using their own protocols. Upon arrival at the reference laboratory, the identification of all isolates was confirmed by the Phoenix Automated System (Becton-Dickinson Diagnosis, Sparks, MD, USA) and the API20E method (bioMérieux, Marcy l'É toile, France). Antibiotic susceptibility testing and ESBL detection were performed by the disc diffusion and microdilution methods following CLSI guidelines.
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Antibiotic susceptibility testing was carried out using the Phoenix Automated System. Antibiotic-susceptible E. coli ATCC 25922 was used as a quality control strain and CTX-M-15-producing E. coli 222 3 was used as a positive control.
Molecular epidemiology
The genetic relationship between all 162 K. pneumoniae isolates was determined by PFGE after total chromosomal DNA digestion with XbaI. 3 A selected sample of 29 K. pneumoniae isolates (8 from H1, 10 from H2, 4 from H3, 3 from H4 and 4 from H5), representing the different PFGE clusters and other parameters such as the number of cases per hospital and clinical relevance, was studied further to determine: (i) the MLST types according to the Institut Pasteur scheme for K. pneumoniae (http://www.pasteur.fr/recherche/ genopole/PF8/mlst/Kpneumoniae.html; last accessed February 2009); and (ii) the presence of other antibiotic resistance genes (see below).
The phylogenetic relationships among the different STs found in this study were established according to the eBURST program (version 2, http://linux.mlst.net/burst.htm).
Characterization of antibiotic resistance genes
Genes encoding ESBL enzymes (CTX-M, SHV and TEM types), bla OXA-1 , the aac(3)-IIa aminoglycoside resistance gene and the aac(6 0 )-Ib-cr aminoglycoside-quinolone resistance gene were characterized by PCR amplification with specific primers and DNA sequencing. 3 Screening of qnrA, qnrB and qnrS plasmidic quinolone resistance genes was carried out by multiplex PCR as described by Robicsek et al. 11 The qnr subtypes were characterized according to the mutation profiles described by Jacoby et al.
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The amplification and sequence analysis of the quinolone resistance determining region (QRDR) of gyrA and parC were performed as previously described. 13 
Conjugation assay and plasmid characterization
Conjugation experiments were carried out using the kanamycinazide-resistant E. coli BM101 as a recipient. Putative transconjugants were selected on Mueller-Hinton agar plates containing kanamycin (100 mg/L), azide (160 mg/L) and cefotaxime (4 mg/L).
Plasmids were classified according to their incompatibility group by a PCR-based replicon-typing scheme. 14 
Results and discussion
Of the 162 K. pneumoniae isolates, 58 (35.8%) produced clinical infections: 31 (53.4%) urinary tract infections (UTIs), 24 (41.4%) blood infections and 3 (5.2%) other infections. The remaining 104 isolates (64.2%) were colonizers isolated from rectal swabs (n¼81, 77.9%), respiratory tract samples (n¼12, 11.5%) and skin (n¼11, 10.6%).
Sixty-nine (42.6%) isolates were collected from newborns (54 from H2, 10 from H3 and 5 from H5) and 93 (57.4%) were collected from adults (82 from H1, 8 from the ICU of H3 and 3 from the Geriatric Unit of H4).
All 162 isolates were identified as ESBL producers according to phenotypic reference methods, and the bla CTX-M-15 gene was detected in all isolates by PCR and DNA sequencing.
At a genetic linkage of .75%, PFGE results revealed seven well-defined clusters (Figure 1 ). Cluster 1 (C1) included all 82
isolates from H1, all of them from adults. Two different clusters were detected for isolates from H2, both from newborns: cluster 2 (C2) contained 41 isolates collected between January and March 2008 and cluster 3 (C3) contained 5 isolates collected in December 2008. Two PFGE clusters were detected for isolates from H3; cluster 4 (C4) contained 10 isolates from the newborn unit and cluster 5 (C5) contained 8 isolates from the adult ICU. Cluster 6 (C6) included three isolates from adults in H4 and cluster 7 (C7) included five isolates from newborns in H5 (Table 1) .
According to the MLST analysis, the seven PFGE clusters corresponded to seven different K. pneumoniae STs: PFGE C1 isolates belonged to ST1; C2 to ST35; C3 to ST20; C4 to ST36; C5 to ST14; C6 to ST11; and C7 to ST17 (Table 1) . Analysis of STs by eBURST showed that ST20 is a single-locus variant of ST17 and that ST36 is a double-locus variant of ST35.
All CTX-M-15-producing K. pneumoniae clones were resistant to multiple antibiotics. In addition to resistance to all penicillins and cephalosporins, the following multiresistance patterns were observed: non-susceptibility to co-amoxiclav/gentamicin/ tobramycin in C2/ST35, C3/ST20 and C7/ST17 clones, all of which were isolated from newborns; non-susceptibility to co-amoxiclav/tobramycin/ciprofloxacin in the C1/ST1 clone from adults; non-susceptibility to co-amoxiclav/gentamicin/ tobramycin/ciprofloxacin/co-trimoxazole in C5/ST14 and C6/ ST11 clones from adults; and non-susceptibility to co-amoxiclav/ gentamicin/tobramycin/ciprofloxacin in C4/ST36 clone from newborns (Table 1) .
In addition, one C5/ST14 isolate exhibited decreased susceptibility to imipenem (MIC 4 mg/L), meropenem (MIC 8 mg/L) and ertapenem (MIC. 4 mg/L). Further screening of this isolate to detect carbapenemases and cephalosporinases of the AmpC-type was negative; therefore, other resistance mechanisms such as modifications to the major outer membrane proteins (OMPs) may be implicated in this multiresistance profile in addition to CTX-M production, as previously described. 15 All seven clones of CTX-M-15-producing K. pneumoniae tested positive for the bla OXA-1 and aac(6 0 )-Ib-cr aminoglycosidequinolone resistance genes. In addition, all clones except C1/ST1 also contained the aac(3)-IIa aminoglycoside resistance gene ( Table 1 ). The simultaneous production of bla OXA-1 and bla CTX-M-15 explains the resistance to co-amoxiclav, a fact that limits the therapeutic options, particularly in UTIs.
The three clones for which ciprofloxacin MICs were .2 mg/L had the following mutations in GyrA: Ser-83!Ile (C1/ST1), Ser-83!Tyr (C5/ST14), Ser-83!Phe (C6/ST11) and Asp-87!Ala (C6/ST11) ( Table 2 ). In addition C1/ST1 and C6/ST11 clones also had the Ser-80!Ile substitution in ParC. The three clones for which ciprofloxacin MICs were 0.12 mg/L had no changes in the QRDRs. In general the CTX-M-15-producing K. pneumoniae isolated from adult patients were resistant to ciprofloxacin (MICs . 2 mg/L) compared with isolates from newborns, which were susceptible to this antibiotic (Table 1) . However, C4/ST36 isolates from newborns of H3 with an MIC of ciprofloxacin of 2 mg/L possessed the qnrS1 gene without mutations in the QRDRs (Table 2) .
Two subtypes of qnrB were detected. qnrB4 was found in one isolate of the C7/ST17 clone collected from a newborn; this isolate was free of QRDR mutations and had a ciprofloxacin MIC of 1 mg/L. The remaining C7/ST17 isolates that were negative for qnrB4 presented ciprofloxacin MICs 0.12 mg/L. qnrB1 was identified in one adult isolate of the C6/ST11 clone, which had a ciprofloxacin MIC . 2 mg/L and also had the QRDR mutations described above (Table 2) .
In four of the seven (57.1%) clones studied, C2/ST35, C3/ST20, C5/ST14 and C7/ST17, the bla CTX-M-15 gene was positively mobilized by conjugation. In all cases, plasmids of the incompatibility group IncF were identified; all transconjugants carried the FII and FIB replicons and were 100% homologous with that of plasmid pC15-1a (GenBank accession no. AY458016), described in a CTX-M-15-producing E. coli in Canada. Transconjugants also had the bla OXA-1 , aac(6 0 )-Ib-cr and aac(3)-IIa genes.
We previously reported the clonal dissemination of CTX-M-15-producing E. coli in Spain. 3 We now describe the emergence of this same enzyme in K. pneumoniae. As in E. coli, acquisition of CTX-M-15 by K. pneumoniae is associated with multiple drug resistance but the epidemiology appears to be different, exhibiting a multiclonal distribution in this study.
None of the CTX-M-producing STs detected in this study was found in more than one hospital, although some STs were detected in different departments of a single hospital (H3). Taken together, our results indicate that a number of previously circulating nosocomial clones of K. pneumoniae have acquired the CTX-M-15 gene, in contrast to the single CTX-M-producing E. coli O25:H4-ST131 that has been clonally disseminated throughout various countries worldwide. These findings may suggest that the occurrence of CTX-M-15-producing K. pneumoniae does not represent the same level of threat as CTX-M-15-producing E. coli.
To date, little is known about the population structure of CTX-M-15-producing K. pneumoniae. Dissemination of three major CTX-M-15-producing K. pneumoniae epidemic clones, ST11, ST15 and ST147, was recently described in Hungary. 4 One of these, ST11, was also found in the present study. The first report on the development and evaluation of the MLST scheme for K. pneumoniae tested 67 nosocomial isolates from different countries and identified five of the seven STs described in the present study (1, 17, 20, 35 and 36) . 16 STs 1 and 35 were initially described in K. pneumoniae isolates from Spain. 16 The recent and rapid emergence of CTX-M-15 as one of the most important epidemic ESBLs in E. coli has probably generated an important genetic reservoir from which other species that share the same ecological environment as E. coli, such as K. pneumoniae, could easily acquire this resistance gene. CTX-M-15-producing K. pneumoniae in Spain
In E. coli, bla CTX-M-15 is linked to epidemic IncFII and IncFI plasmids; 17, 18 this could be the case for CTX-M-15-producing K. pneumoniae as described in this study.
In conclusion, this study shows that CTX-M-15-producing K. pneumoniae strains of STs 1, 11, 14, 17, 20, 35 and 36 are spreading as pathogens and colonizers among newborn and adult patients in Spain. Our findings show that CTX-M-15 has now spread into several clones of K. pneumoniae, conferring resistance to multiple antibiotics and presenting new epidemiological and clinical challenges.
